Introduction
Despite great improvements in treatment results of childhood acute lymphoblastic leukemia (ALL) during the past decades, approximately 15-20% of the children die from the disease or complications to treatment. 1 The majority of relapses occur in the bulk group of patients (low-risk patients), and identification of additional risk-factors at diagnosis is needed to further individualize treatment to minimize relapses and late effects of overtreatment. The treatment stratification in the Nordic countries today is based on upfront risk criteria and response to treatment measured morphologically. 1, 2 Minimal residual disease (MRD) has been shown to be a powerful predictor of treatment outcome [3] [4] [5] [6] and several study groups already use MRD to select consolidation and further therapy. 7, 8 In the Nordic Society of Pediatric Hematology and Oncology (NO-PHO) ALL 2000 protocol, the impact of MRD is currently under evaluation, but is not used for stratification.
Solid neoplasms as well as hematological malignancies are dependent on interactions with their microenvironment for growth and survival, 9 and for leukemia this process occurs in the bone marrow (BM) stroma. In some cases, BM fibrosis develops concurrently with leukemia. A new semiquantitative scoring system regarding grading of BM fibrosis has recently been established, and several studies have shown that BM fibrosis evaluated by both semiquantative and stereological methods is associated with a poor prognosis for patients with chronic myeloid leukemia (CML). [10] [11] [12] Wallis and Reid 13 found a significant association between the presence of BM fibrosis and B-cell lineage in childhood ALL. Thomas et al. 14 confirmed this association in adult B-cell lineage ALL, but found no prognostic significance.
Several in vitro studies support the importance of the interaction between BM stroma and leukemic cells. [15] [16] [17] Morphological studies investigating the significance of the BM stroma are rare in childhood ALL. We have previously shown a prognostic impact of BM fibrosis measured as reticulin fiber density (RFD) at diagnosis in childhood ALL. 18 From clinical experience, it is known that when patients present with pathological BM fibrosis at diagnosis it will vanish during initial treatment in most ALL cases, but the dynamics and significance of this process are largely unknown. We hypothesized that a high RFD at diagnosis could influence the ability of chemotherapy to reach the leukemic cells and that the rate of reduction of fibrosis may indirectly reflect treatment response. The aim of the present study was to investigate the relation between RFD and other known risk factors and to further evaluate the prognostic impact of RFD at diagnosis and at treatment day 29 for various subgroups of patients, especially within the low-risk group.
Patients and methods

Patients
We retrospectively studied 166 BM iliac crest biopsies obtained at diagnosis from children 41 and o15 years of age with ALL (B-cell precursor (BCP), n ¼ 146; T cell, n ¼ 20), and 62 BM biopsies obtained at treatment day 29 from BCP patients only. Patients were diagnosed in the period 1992-2006 at the childhood oncology centers in Umeå, Uppsala and Stockholm, Sweden. The biopsies obtained on treatment day 29 were all from patients diagnosed in Umeå. Diagnosis was established by morphology, immunophenotyping and cytogenetic analysis. All patients were treated according to the NOPHO ALL protocols 1992 (n ¼ 98) or 2000 (n ¼ 68). Patients with Down's syndrome and patients with t(9;22) were excluded. The only criterion for inclusion in the study was sufficient technical quality of the diagnostic BM biopsy. Samples were considered to be of insufficient quality if they could not be stained with a panel of antibodies against blood vessels and for reticulin fibers or when they were too crushed and distorted for evaluation or when the total area possible to evaluate was less than three marrow spaces. Of 433 patients diagnosed in the three centers during the time of the study (eligible patients), 166 had biopsies of sufficient quality available. As illustrated in Table 1 , the biopsy frequency and success rate differed between the three centers. In Umeå and Uppsala, BM biopsy has been a routine sample at diagnosis since 1992. In Stockholm this routine started around 2001 and the earlier samples (n ¼ 10) are likely to have been taken because of difficulties in obtaining an aspirate. In all centers, the success rate of obtaining BM biopsies of proper quality has improved considerably since a BM biopsy needle with an acquisition system was introduced during the twentyfirst century.
The 166 included patients did not differ significantly from the 267 patients with missing or insufficient material for any of the examined variables except age and follow-up (Table 2) . Included patients were olderFmedian 5.0 years at diagnosisFas compared to 4.0 years for patients who were not included, and follow-up for patients remaining in continuous complete remission (CCR) was longer for patients who were not analyzed. The latter reflected that the majority of material studied was obtained later during the study period. When 62 BCP patients, examined for RFD on day 29, were compared to all BCP patients eligible, the results were similar as for the comparison between the 166 included patients and 267 eligible patients (data not shown).
The NOPHO ALL 1992 protocol has been previously described. 1 Compared to the 1992 protocol, the 2000 protocol had the same backbone with minor changes. As illustrated in Supplementary 19 All biopsies were embedded in paraffin. BM sections of 5 mm were stained with silver impregnation for visualization of reticulin fiber content. 20 All readings/estimations were performed in a blinded manner. RFD was defined as volume reticulin fibers per volume reference tissue, that is, the percentage of BM tissue occupied by reticulin fibers, and was assessed in all samples. Using a 121-point eyepiece graticule representing 0.06 mm 2 at Â 400 magnification in 10 randomly selected fields within the marrow area, the number of graticule-crossing points (hits) overlaying reticulin fibers (as marked in Figure 1 ) and hits over reference space (remaining BM area) were counted. 21 The BM fields were randomly selected. This was achieved by defocusing the section in the microscope before selection of the next microscopy field to the point where reticulin fibers could not be seen, but the difference between BM area and bone was still apparent. The fiber volume density was assessed by one investigator (UNN) and a very good correlation was obtained when 20 BM sections were reanalyzed and recalculated over 10 different randomly selected fields (r ¼ 0.90, 95% CI: 0.76-0.96, Po0.001).
Detection of minimal residual disease by flow cytometry (MRD flow)
A stain and lyse/wash technique was used for surface markers, followed by fixation and permeabilization of the intracellular Table 1 Biopsy frequency at the three diagnostic centers and reasons for exclusions In Uppsala seven biopsies were embedded in plastic and thereby missing in this study. Bone marrow fibrosis in childhood ALL U Norén-Nyström et al processed markers according to the manufacturer's instructions. Data acquisition was performed using FACS-Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA). Light scatter characteristics and autofluorescence levels of normal peripheral lymphocytes were used as references values for instrument settings. At diagnosis, a total of 15 Â 10 3 nongated events were acquired. At follow-up, a two-step acquisition procedure was applied with a live-gate set on the basis of lineage marker expression and characteristic side scatter; an acquisition of at least 250 Â 10 3 nongated events were applied. The details of these procedures have been previously described. 3 The analyses were performed at three different laboratories (Umeå, Uppsala and Stockholm) using the same protocol. Some samples were exchanged and double-tested to minimize interlaboratory variability (details to be published separately).
Statistics
The intraclass correlation coefficient was used to analyze reproducibility of the RFD method. Differences in RFD between males and females, risk-groups, patients with or without CNS-disease, BCP-and T-immunophenotype and cytogenetic subgroups were analyzed using the Mann-Whitney U-test. The Spearman's correlation test was used to analyze correlation between RFD at diagnosis and white blood cell (WBC) count, age and MRD flow on day 29. For correlation analyses, both WBC values and MRD measurements were logarithmically transformed. MRD values of zero were set to the maximum possible value according to sensitivity for each sample. The relation between sex and RFD for patients with a high-hyperdiploid (HeH) karyotype (51-61 chromosomes) was analyzed by the w 2 -test. Survival curves were constructed using the Kaplan-Meier method and differences in outcome between subgroups were tested with the log-rank test. An event was defined as relapse of disease. The time to relapse was defined as the interval in years between diagnosis and the event. In survival analyses, that is, Kaplan-Meier and Cox's regression, children remaining in CCR were censored at the last known time of follow-up. For the same analyses, patients who died in remission (n ¼ 3) were excluded. Among the 166 patients with RFD evaluated, no patients were found with resistant disease, induction failure or secondary malignancy (SMN). Six patients died in remission, that is, three BCP-and three T-ALL patients. Among the other 267 patients eligible for the study, one SMN, one induction death, two deaths in remission and two patients with resistant disease were noticed. The level of statistical significance was defined as Po0.05 (two-sided). All data were analyzed using SPSS 15.0 software for Windows (SPSS, Chicago, IL, USA).
Results
RFD results were compared between the three hospitals from which samples were obtained (details in Supplementary  Table 2 ). RFD in BCP-ALL patients did not differ between Umeå and Uppsala (P ¼ 0.079) or between Umeå and Stockholm (P ¼ 0.085). However, RFD was higher in BM sections from patients diagnosed in Uppsala when compared to patients diagnosed in Stockholm (P ¼ 0.004). The clinical characteristics for BCP-ALL patients from the three hospitals are presented in Supplementary Table 2 . Representative pictures of high and low RFD are shown in Figure 1 .
RFD is higher in B-cell precursor compared to T-ALL
As illustrated in Figure 2 , RFD was higher in BCP-ALL patients (median: 17.2% (25th and 75th percentile: 13.3 and 22.2) n ¼ 146) as compared to patients with T-cell ALL (T-ALL) (12.7% (9.4; 13.5) n ¼ 20, Po0.001). This difference remained when only HR BCP patients (16.8%, n ¼ 21) were compared to patients with T-ALL (12.7%, n ¼ 20, P ¼ 0.002; not shown in figure) . No difference in RFD was found between LR and HR BCP patients.
RFD is correlated to WBC count and MRD
RFD correlated negatively with WBC count when BCP-ALL patients were analyzed (log values of WBC, n ¼ 146, r ¼ À0.22, P ¼ 0.008). Patients with WBC count 450 Â 10 9 per liter (WBC cutoff for HR-ALL) and RFD 420.6% (cutoff used for high RFD, see below) were rare, only two among a total of 166 patients had this combination with BCP immunophenotype. There was a borderline negative correlation between age and RFD (r ¼ À0. 16 , P ¼ 0.052). No other patient characteristics or Figure 1 Examples of reticulin staining of bone marrow (BM) sections at diagnosis of childhood acute lymphoblastic leukemia (ALL). Sections representative for low and high reticulin fiber density (RFD), respectively. BM biopsies obtained at diagnosis. Both images at a magnification of Â 400. White circles marks graticule-crossing points overlaying reticulin fibers. Note that the graticule used for illustration only contains 36 intersections whereas the one used for calculation contained 121.
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U Norén-Nyström et al diagnostic features (sex, risk-group, CNS-disease, cytogenetic subgroups) were found to be associated with RFD at diagnosis in BCP patients. BM MRD measurements by flow cytometry obtained on treatment day 29 were available for 44 BCP-ALL patients. RFD at diagnosis correlated with MRD flow on day 29 (Figure 3a , P ¼ 0.001) and this was also true when only LR BCP patients were included (n ¼ 37, r ¼ 0.48, P ¼ 0.002; not shown in figure) . BCP patients with MRD flow X10 À4 on day 29 presented with a higher RFD at diagnosis compared to the patients with MRD flow o10 À4 (n ¼ 39; Figure 3b , P ¼ 0.003; five samples with zero MRD did not reach the 10 À4 sensitivity level and were excluded). This difference was also seen in separate analysis of LR BCP patients (n ¼ 33, MRD X10 À4 , n ¼ 14, o10
À4
, n ¼ 19, P ¼ 0.008; not shown in figure) . Similar significant differences were found when an MRD flow cutoff at 10 À3 was used (data not shown).
When patients not achieving morphological remission on day 29 were excluded from analysis (n ¼ 2), the correlation between MRD flow on day 29 and RFD at diagnosis was still significant, in all BCP patients (n ¼ 42, r ¼ 0.43, P ¼ 0.004) and in LR BCP patients (n ¼ 35, r ¼ 0.43, P ¼ 0.010).
RFD is related to outcome in high-hyperdiploid patients
BCP-ALL is a heterogeneous group from a cytogenetic point of view. The most common cytogenetic subgroup in childhood ALL, HeHFwhich is known to have a favorable outcome 22 Fwas possible to investigate separately in this study (n ¼ 53). As illustrated in Table 3A and B, the prognostic impact of RFD was explored in Cox's analyses for all BCP patients, LR BCP patients and the LR BCP group subdivided in HeH patients and non-HeH patients. Univariate analysis in the LR HeH group revealed a significant impact of RFD (relative risk (RR) ¼ 1.16, P ¼ 0.003). Our findings indicate that RFD was of prognostic value for the LR HeH subgroup only, but not for other BCP-ALL patients. This was further illustrated in a Kaplan-Meier survival analysis. The cutoff used for low and high RFD was decided by exploring RFD data in Cox's analyses dividing the material by the median, in thirds and quartiles. The highest RR was found for patients with a RFD value of 420.6% representing the upper third of patients with BCP-ALL.
Within the LR HeH group (n ¼ 53), patients with a high RFD had an inferior outcome with a probability of relapse-free survival (pRFS) of 49 ± 15%, compared to 92 ± 6% for patients with a low RFD (P ¼ 0.002, Figure 4a ). In accord with this result, relapsed LR HeH patients presented with a higher RFD at diagnosis when compared to patients remaining in CCR, as illustrated in Figure 4b (P ¼ 0.006). We found an overrepresentation of boys in HeH patients with high RFD where the boy:girl ratio was 13:4 (3.25) compared to 15:21 (0.71) in HeH patients with low RFD (P ¼ 0.018). As illustrated in Table 3A , RFD did not have a prognostic impact among non-HeH LR patients, and the distribution of sexes was not skewed. No difference in RFD was found between HeH LR patients (n ¼ 53) and non-HeH LR patients (n ¼ 70, P ¼ 0.709).
Induction treatment associated changes in RFD are related to outcome
To investigate if induction treatment reduced the degree of fibrosis, RFD was calculated for BM sections obtained on treatment day 29 for 62 BCP-ALL patients. As mentioned, no difference in RFD was found at diagnosis between boys and girls in the BCP group. However, on day 29, boys had a tendency to higher RFD (7.9% (4.3; 12.9)) compared to girls (4.7% (2.9; 9.5), P ¼ 0.064). In survival analysis, no prognostic impact was found for the day 29 RFD value as such, but when relating RFD obtained on day 29 to that at diagnosis, three different groups of patients were identified. The median change in RFD on day 29 was a reduction of 8.4 (5.9; 15.4) percentage points in absolute numbers for all 62 BCP patients. The rate of RFD reduction was found to be of prognostic importance for patients with low RFD at diagnosis (RFD o20.6%). This group had a very favorable outcome if RFD on day 29 was reduced more than the median value of reduction (pRFS: 100%, Figure 5 , group A). Patients with low RFD at diagnosis and less than the median reduction on day 29 did worse (pRFS: 66±13%, Figure 5 , group B, P ¼ 0.041). For patients with a high RFD at diagnosis, the rate of reduction made no difference in survival analysis (not included in the analysis in Figure 5 ). The HeH patients in this analysis (n: 24) were equally distributed between the three groups; eight in group A, nine in group B and seven in the group with high RFD at diagnosis. When analyzing the relative change in RFD from diagnosis on day 29 instead of the absolute, results were comparable (data not shown).
To explore if differences in RFD between centers could influence our results, all statistics were recalculated with RFD as standardized values for each hospital, but this had no effect on our conclusions (data not shown).
Discussion
Features representing the leukemia cell microenvironment or interactions between leukemic and surrounding cells have generally not been investigated or proposed as potential stratifying factors for treatment of childhood ALL. However, there is emerging recognition of the importance of tumor stroma in solid tumors. 9 In hematological malignancies, tumor cells also interact with their stromal microenvironment through cellsurface receptors, 23 leading to increased production of matrix metalloproteinases, 24, 25 altered expression of extracellular matrix receptors 26 and increased angiogenesis. 27, 28 We have previously found BM fibrosis to be barely prognostic when all patients (both BCP-and T-immunophenotype and cytogenetic) were analyzed in a retrospective study of 81 childhood ALL patients. 18 In the present study, the material was expanded with the aim to evaluate possible associations of fibrosis to known favorable or unfavorable features and to investigate prognostic impact in defined subgroups. The RFD method assessing fibrosis based on stereology was chosen since it is easy and objective and has the advantage of resulting in a continuous variable in statistic analyses. Similar to the results in Table 3 Cox's regression RFD Bone marrow fibrosis in childhood ALL U Norén-Nyström et al our previous study, 18 RFD was not prognostic in all LR patients. However, RFD was in the present larger set of patients found to be prognostic in the LR subgroup of HeH ALL patients with no high-risk criteria. In relapsed patients in the NOPHO ALL 1992 protocol, HeH is one of the most common cytogenetic abberations (preliminary results). Our results indicate that RFD is candidate as a stratifying factor for HeH patients, and since most of these patients today receive LR treatment HeH patients with high RFD might benefit from being upgraded.
Among HeH patients, a sex difference was found, that is, an overrepresentation of boys with high RFD. It would be interesting to investigate a larger set of HeH patients to confirm these data. This interaction of sex with HeH and the previously known difference in age (HeH patients are younger than the average BCP patient) can explain the differences of RFD between univariate and multivariate Cox's analysis.
There is emerging evidence that marrow fibrosis is prognostic and predictive of therapy failure and accelerated phase in CML patients. 29 In this context, it was intriguing to find the association between high RFD at diagnosis and high MRD on treatment day 29 in the present study of childhood ALL, as it suggests that a high degree of fibrosis at diagnosis influences early treatment response. MRD is one of the most powerful prognostic factors, implemented as a treatment stratifying factor in many contemporary therapy protocols for childhood ALL, including the ongoing AIEOP/BFM ALL-2000, the DCOG-ALL 10 protocols and the current ALL protocol at St Jude Children's Research Hospital (Total Therapy Study XV). Therefore, it was interesting to find a factor measurable at diagnosis that correlated to MRD. The reason for this association is not known, but one simple explanation could be that fibrosis prevents drugs from reaching leukemic cells in sufficient concentrations. Fibrosis in the BM may also be a marker for a biological subtype of ALL less sensitive to chemotherapy for other reasons. The correlation between MRD on day 29 and RFD at diagnosis was still present when patients who failed to reach morphological remission were excluded, indicating that it was valid also at the submicroscopic level.
Patients with low RFD at diagnosis but with a slow RFD reduction rate had an unfavorable outcome. It would be interesting to relate this phenomenon to MRD, since the rate of reduction of fibrosis could reflect a primary treatment response or a secondary phenomenon. Unfortunately, we did not have enough MRD data to perform this correlation analysis. Obtaining such data should be a major objective of future studies. Irrespective of the reasons behind the association between high RFD at diagnosis and slow response to treatment, we speculate that BM fibrosis is leukemia driven and lingering fibrosis could be a sign of remaining leukemia.
The tentative difference between boys and girls regarding RFD on day 29 was surprising. It is known from previous studies that boys have a slightly worse prognosis compared to girls. [30] [31] [32] The reasons for this are not well understood. Differences in pharmacokinetics between sexes have been suggested, but when investigated rendered in conflicting results. 30, 33, 34 There was a marked difference in RFD between BCP-and T-ALL patients. This finding is in line with a previous publication, 13 and further emphasizes the distinction between these two entities and the need for analyzing and maybe also treating them separately.
RFD was found to be negatively correlated to WBC count. Since the mechanisms for high WBC count in peripheral blood in leukemia patients are not fully understood, this result invites speculation. Are leukemic cells within a BM with a high degree of fibrosis more stuck to surrounding stromal tissue? Is BM fibrosis restricting leukemic cells from reaching blood vessels or do these leukemias simply constitute a subtype with a low tumor burden? These questions remain to be answered.
Our results further stress the importance of the BM stroma in acute leukemia and the need for additional studies to understand underlying mechanisms as well as larger prospective studies to confirm the prognostic findings as well as a possible association with MRD. An expanded use of BM biopsy at diagnosis and during follow-up is central for performing these studies and also for increasing the clinical experience.
